141 related articles for article (PubMed ID: 8425186)
1. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats.
Hamers FP; Brakkee JH; Cavalletti E; Tedeschi M; Marmonti L; Pezzoni G; Neijt JP; Gispen WH
Cancer Res; 1993 Feb; 53(3):544-9. PubMed ID: 8425186
[TBL] [Abstract][Full Text] [Related]
2. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats.
Tredici G; Cavaletti G; Petruccioli MG; Fabbrica D; Tedeschi M; Venturino P
Neurotoxicology; 1994; 15(3):701-4. PubMed ID: 7854609
[TBL] [Abstract][Full Text] [Related]
3. Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons.
Müller LJ; Gerritsen van der Hoop R; Moorer-van Delft CM; Gispen WH; Roubos EW
Cancer Res; 1990 Apr; 50(8):2437-42. PubMed ID: 2156619
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective interactions in rats between paclitaxel and cisplatin.
McKeage MJ; Haddad GG; Ding L; Galettis P; Screnci D; Zhuang L; Baguley BC
Oncol Res; 1999; 11(6):287-93. PubMed ID: 10691031
[TBL] [Abstract][Full Text] [Related]
5. Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat.
McKeage MJ; Boxall FE; Jones M; Harrap KR
Cancer Res; 1994 Feb; 54(3):629-31. PubMed ID: 8306321
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.
Hamers FP; Pette C; Bravenboer B; Vecht CJ; Neijt JP; Gispen WH
Cancer Chemother Pharmacol; 1993; 32(2):162-6. PubMed ID: 8387400
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy.
Meijer C; de Vries EG; Marmiroli P; Tredici G; Frattola L; Cavaletti G
Neurotoxicology; 1999 Dec; 20(6):883-7. PubMed ID: 10693969
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth.
Bianchi R; Gilardini A; Rodriguez-Menendez V; Oggioni N; Canta A; Colombo T; De Michele G; Martone S; Sfacteria A; Piedemonte G; Grasso G; Beccaglia P; Ghezzi P; D'Incalci M; Lauria G; Cavaletti G
Eur J Cancer; 2007 Mar; 43(4):710-7. PubMed ID: 17251006
[TBL] [Abstract][Full Text] [Related]
9. [Glutathione chemoprotection therapy against CDDP-induced neurotoxicity in patients with invasive bladder cancer].
Sumiyoshi Y; Hashine K; Kasahara K; Karashima T
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1506-8. PubMed ID: 8854791
[TBL] [Abstract][Full Text] [Related]
10. Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study.
Rodriguez-Menendez V; Gilardini A; Bossi M; Canta A; Oggioni N; Carozzi V; Tremolizzo L; Cavaletti G
Anticancer Res; 2008; 28(1A):335-42. PubMed ID: 18383866
[TBL] [Abstract][Full Text] [Related]
11. Nerve growth factor prevents experimental cisplatin neuropathy.
Apfel SC; Arezzo JC; Lipson L; Kessler JA
Ann Neurol; 1992 Jan; 31(1):76-80. PubMed ID: 1543351
[TBL] [Abstract][Full Text] [Related]
12. Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats.
Tredici G; Braga M; Nicolini G; Miloso M; Marmiroli P; Schenone A; Nobbio L; Frattola L; Cavaletti G
Exp Neurol; 1999 Oct; 159(2):551-8. PubMed ID: 10506527
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.
Meregalli C; Canta A; Carozzi VA; Chiorazzi A; Oggioni N; Gilardini A; Ceresa C; Avezza F; Crippa L; Marmiroli P; Cavaletti G
Eur J Pain; 2010 Apr; 14(4):343-50. PubMed ID: 19695912
[TBL] [Abstract][Full Text] [Related]
14. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
Chan P
Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
[TBL] [Abstract][Full Text] [Related]
15. BGP-15, a hydroximic acid derivative, protects against cisplatin- or taxol-induced peripheral neuropathy in rats.
Bárdos G; Móricz K; Jaszlits L; Rabloczky G; Tory K; Rácz I; Bernáth S; Sümegi B; Farkas B; Literáti-Nagy B; Literáti-Nagy P
Toxicol Appl Pharmacol; 2003 Jul; 190(1):9-16. PubMed ID: 12831778
[TBL] [Abstract][Full Text] [Related]
16. Glutathione depletion increases brain susceptibility to m-dinitrobenzene neurotoxicity.
Hu HL; Bennett N; Holton JL; Nolan CC; Lister T; Cavanagh JB; Ray DE
Neurotoxicology; 1999 Feb; 20(1):83-90. PubMed ID: 10091861
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity.
Callizot N; Andriambeloson E; Glass J; Revel M; Ferro P; Cirillo R; Vitte PA; Dreano M
Cancer Chemother Pharmacol; 2008 Nov; 62(6):995-1007. PubMed ID: 18270703
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer.
van der Gaast A; Kok TC; Kerkhofs L; Siersema PD; Tilanus HW; Splinter TA
Br J Cancer; 1999 Jun; 80(7):1052-7. PubMed ID: 10362115
[TBL] [Abstract][Full Text] [Related]
20. Sex-related differences in cisplatin-induced neuropathy in rats.
Wongtawatchai T; Agthong S; Kaewsema A; Chentanez V
J Med Assoc Thai; 2009 Nov; 92(11):1485-91. PubMed ID: 19938741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
